Email this article 
Trends in the treatment of cytomegalovirus infection in oncohematological patients
- Authors: Balashov D.N.1
-
Affiliations:
- Dmitriy Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
- Issue: Vol 8, No 1 (2013)
- Pages: 46-51
- Section: HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CARE
- Published: 22.02.2013
- URL: https://oncohematology.abvpress.ru/ongm/article/view/43
- DOI: https://doi.org/10.17650/1818-8346-2013-8-1-46-51
- ID: 43
Cite item
Full Text
Abstract
Cytomegalovirus (CMV)-related complications remain an extremely serious and urgent problem in immunocompromised patients. Ganciclovir (GCV) is efficient for the treatment of CMV-infection, but myelotoxicity limits the possibilities of their application. In addition, prolonged or intermittent courses of antiviral drugs predispose to the development of CMV drug-resistant strains. Valganciclovir is a safe and effective alternative to intravenous GCV. Despite the well-spread application of effective methods of early detection and pre-emptive treatment, the issue of the control of CMV-infection is not resolved. High intensive immunoablative therapy (alemtuzumab, ATG, еtс.) and hematopoietic stem cell transplantation (HSCT) from alternative donors greatly increase the risk of life-threatening visceral CMV-infections in patients. Thereby, studies of new therapeutic approaches (for example, transfusion of CMV-specific T-cells) are actually in process.
About the authors
D. N. Balashov
Dmitriy Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Author for correspondence.
Email: bala8@yandex.ru
Russian Federation
References
Supplementary files
